에 대한 최신 뉴스 Elastic (NYSE:ESTC) 주식

Elastic

Elastic is a software company based in Mountain View, California, focusing on search-adjacent products. Its search engine allows it to process both structured and unstructured data while gleaning insights from that data. The firm's primary focus is on enterprise search, observability, and security.

Earnings

News

Guidance

Global

After-Hours Center

Movers

ESTC

엘라스틱 N.V.(NYSE:ESTC)는 목요일 시장 마감 후 1분기 재무 결과를 발표했다. 이 발표로 주가는 시간외 거래에서 24% 이상 급락했다. 주요 수치는 다음과 같다.  

엘라스틱의 주식은 양호한 1분기 실적에도 약한 2분기 매출 전망에 24% 이상 급락

COHR

COIN

CRWD

GWRE

ILMN

NVDA

PLTR

RDDT

SAIA

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 가이드와이어 소프트웨어(NYSE:GWRE)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 예상보다 높은 2024회계연도 매출 지침을 발표한 후 14.08% 급등했다. 몇몇 분석가는 예측치를 상향 조정했다. 

Arm과 보잉은 지난주 최고의 성과를 보인 10개의 대형주 중 일부 (6월 1일-6월 7일)

Elastic NV

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BJDX

SMST

LIFW

SMCX

LIFWW

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Markets

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

Elastic: This Is A Dip Worth Buying (Rating Upgrade)

Software & Internet Analyst Thill provides an update into the world of Observability (relevant companies DDOG, DT, ESTC) on an Analyst/Industry con...

Jefferies Internet and software analyst to hold analyst/industry conference call

Tracking Baillie Gifford's 13F Portfolio - Q3 2024 Update

Artisan Global Discovery Fund Q3 2024 Commentary

Barclays analyst Raimo Lenschow maintained a Buy rating on Elastic (ESTC – Research Report) today and set a price target of $95.00. The company's s...

Elastic (ESTC) Gets a Buy from Barclays

Analysts have been eager to weigh in on the Technology sector with new ratings on Eventbrite (EB – Research Report), Dayforce Inc (DAY – Research R...

Analysts Offer Insights on Technology Companies: Eventbrite (EB), Dayforce Inc (DAY) and Elastic (ESTC)

TD Cowen analyst Andrew Sherman reiterated a Hold rating on Elastic (ESTC – Research Report) yesterday and set a price target of $80.00. Andrew She...

Elastic's Cloud Growth Challenges and Competitive Pressures Justify Hold Rating

Barclays raised the firm's price target on Elastic (ESTC) to $105 from $95 and keeps an Overweight rating on the shares as part of a earnings previ...

Elastic price target raised to $105 from $95 at Barclays

Fidelity Stock Selector Mid Cap Fund Q3 2024 Review

In a report released today, Brad Reback from Stifel Nicolaus maintained a Buy rating on Elastic (ESTC – Research Report), with a price target of $9...

Stifel Nicolaus Keeps Their Buy Rating on Elastic (ESTC)

ALNY

AMZN

ARGNF

ARGX

AVDX

BWIN

CACI

CHYHY

CPNG

CRTSF

CWAN

DASH

DDOG

DXCM

FIVN

GALDY

GDERF

GRRMF

GRRMY

HUBB

IRTC

ISRG

MANH

MELI

MPWR

MRNA

MSFT

MTSI

NFLX

NVZMF

NVZMY

ONTO

RACE

RPAY

RYAAY

RYAOF

SDZNY

SDZXF

SHOP

SPOT

TBBK

TCOM

TREX

TSLA

TTEK

TTNDF

TTNDY

VEEV

VWDRY

VWSYF

WDAY

WFRD

WFTUF

WING

Press Releases

Elastic Listed in AWS "ICMP" for the US Federal Government

The 2024 Elastic Global Threat Report: Basic Security Settings Are Easily Exploited by Adversaries

Legal

Bragar Eagel & Squire, P.C. Is Investigating iLearningEngines, Elastic, and Acadia and Encourages Investors to Contact the Firm

Elastic Enables Innovation in Next Generation Knowledge Management with LG CNS

Elastic Simplifies Elasticsearch Management with AutoOps Integration

Elastic to Announce Second Quarter Fiscal 2025 Earnings Results on Thursday, November 21, 2024

Elastic Introduces Better Binary Quantization Technique in Elasticsearch

Elastic Announces 100% OpenTelemetry Experience for Kubernetes with the OTel Operator

ELASTIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Elastic N.V. on Behalf of Elastic Stockholders and Encourages Investors to Contact the Firm

Elastic Announces AI Ecosystem to Accelerate GenAI Application Development

ACHC

AILE

Barclays

Guggenheim

Canaccord Genuity

DA Davidson

Rosenblatt

엘라스틱 N.V.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>)는 목요일 시장 마감 후 1분기 재무 결과를 발표했다. 이 발표로 주가는 시간외 거래에서 24% 이상 급락했다. 주요 <a href="https://www.benzinga.com/pressreleases/24/08/b40637612/elastic-reports-first-quarter-fiscal-2025-financial-results">수치</a>는 다음과 같다.
세부 사항: 엘라스틱(Elastic)은 분기별 주당 이익을 35센트로 보고했는데, 이는 분석가들의 합의 추정치인 25센트를 40%나 웃도는 수치이다. 분기별 매출은 3억 4,742만 달러로 컨센서스 예상치를 0.79% 상회했고, 지난해 같은 기간보다 18.27% 증가했다.
<ul>
<li>엘라스틱 클라우드 매출은 1억 5,700만 달러로 전년 대비 30% 증가했다.</li>
<li>연간 계약 금액(ACV)이 10만 달러 이상인 총 고객 수는 1,370명을 넘었다.</li>
<li>전체 구독 고객 수는 약 21,200명이었다.</li>
<li>해당 분기의 순 확장률(Net Expansion Rate)은 약 112%였다.</li>
</ul>
&#8220;우리는 매출과 수익성 모두에서 가이던스의 상단을 초과 달성하며 견고한 1분기 실적을 기록했고, GenAI 제품의 강력한 채택도 계속해서 확인했다. 그러나 연초에 시행한 고객 세분화 변경이 예상보다 더 오래 걸리면서 고객 약정의 양이 영향을 받아 올해는 다소 느리게 시작했다. 이를 해결하기 위해 조치를 취하고 있지만, 올해 매출에 영향을 미칠 것이다&#8221;라고 엘라스틱의 CEO인 애쉬 쿨카르니(Ash Kulkarni)가 말했다.
전망: 엘라스틱은 2분기에 총 매출이 3억 5,300만 달러에서 3억 5,500만 달러 사이가 될 것으로 예상한다. 이는 추정치 3억 6,087만 달러와 비교된다.
ESTC 주가 동향: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>에 따르면, 엘라스틱의 주식은 목요일 애프터 마켓에서 24.54% 하락한 78.21로 거래되었다.
이미지: Elastic N.V. 제공
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>가이드와이어 소프트웨어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 예상보다 높은 2024회계연도 매출 지침을 발표한 후 14.08% 급등했다. 몇몇 분석가는 예측치를 <a href="https://www.benzinga.com//node/39183330" target="_blank" rel="noreferrer noopener">상향 조정했다</a>.</li>
<li>GFL 인바이런먼털(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>)의 주가는 회사가 2건의 인수 제안을 검토하기 위해 금융 자문가를 고용했다는 내용의 보도 이후 11.62% 상승했다.</li>
<li>크라우드스트라이크 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)의 주가는 회사가 강력한 지침을 발표한 후 9.36% 상승했다. 몇몇 분석가들은 예측을 <a href="https://www.benzinga.com//node/39182501" target="_blank" rel="noreferrer noopener">재조정</a>했다.</li>
<li>Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)의 주가가 지난 주 9.26% 상승했습니다. 이는 지난 주에 <a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">엔비디아</a>의 주가가 상승하며 사상 최고치에 가까운 수준에서 거래를 마쳤다는 소식에 이어 일어난 일다.</li>
<li>일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)의 주가가 9.16% 상승했습니다. 이사회는 2024년 6월 12일경에 시작될 것으로 예상되는 &#8216;발행 시점&#8217; 거래인 그레일(GRAIL)의 분사를 승인했다.</li>
<li>사이아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>)의 주식은 8.31% 상승했다. 이는 회사가 <a href="https://www.benzinga.com//node/39155966" target="_blank" rel="noreferrer noopener">4월 근무일당</a> LTL 배송량이 18% 증가했다고 보고한 이후 일어났다.</li>
<li>엘라스틱 N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>)의 주가가 7.65% 상승했습니다.</li>
<li>코히런트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>)의 주가는 6월 3일부터 이사회가 짐 앤더슨(Jim Anderson)을 <a href="https://www.benzinga.com/pressreleases/24/06/g39134653/coherent-appoints-jim-anderson-as-chief-executive-officer" target="_blank" rel="noopener">새로운 CEO</a>로 임명하면서 지난주 7.12% 상승했다.</li>
<li>팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)의 주가가 7.02% 상승했다. 이는 회사의 <a href="https://www.benzinga.com//node/39223353" target="_blank" rel="noreferrer noopener">AIPCon 이벤트</a>가 주식 가격에 영향을 미쳤기 때문다.</li>
<li>보잉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): 2018년과 2019년에 346명의 사망자를 낸 치명적인 충돌 사고에 대해 <a href="https://www.benzinga.com//node/39142764" target="_blank" rel="noopener">경영진이 형사 고발을 당할 가능성이 낮다</a>는 로이터 통신의 보도 이후 지난주 주가는 6.82% 상승했다.</li>
</ol>
위키미디어 커먼즈를 통한 사진
기사 더 읽어보기: <a href="https://www.benzinga.com/news/24/06/39243316/gamestop-and-nio-were-among-the-11-biggest-large-cap-losers-last-week-june-1-june-7-are-these-in-you">게임스탑과 니오는 지난주 최악의 성과를 보인 11개의 대형주 중 일부 (6월 1일-6월 7일)</a>

Comments

Elastic

뉴스

에 대한 최신 뉴스 Elastic (NYSE:ESTC) 주식

금요일, 8월 30, 2024

일요일, 6월 09, 2024

뉴스

파트너 / 기고자

벤징가 글로벌